Active Ingredient(s):Pomalidomide FDA Approved: * February 8, 2013 Pharm Company: *CELGENE Category:Cancer
Pomalidomide (INN; marketed as Pomalyst in the US and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator.[medical citation needed]
Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at ...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion